Propil

Quick links to important sections

Propil

Method of action: Antithyroid, Thyroid Therapy

Treatment option: Hyperthyroidism, Thyrotoxicosis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Propil

Quick Facts: Propylthiouracil

Property Description
Active Ingredient Propylthiouracil (PTU)
Form Oral Tablet (Synthetic)
Pharmacological Class Antithyroid Agent (Thioamide)
Common Use Management of Hyperthyroidism
Origin Synthetic Thioureylene Derivative

What Type of Medicine is Propylthiouracil (Propil)?

Propil is a trade name for the prescription-only drug entity Propylthiouracil (PTU), which is classified as an antithyroid agent. This medication belongs to the thioamide pharmacological group, which comprises compounds structurally recognized for their ability to interfere with thyroid hormone production. Propylthiouracil is typically supplied as a single-ingredient product in an oral tablet dosage form. The designation as a thioamide is significant as it sets Propylthiouracil apart from treatments like radioactive iodine or iodide solutions. It is clinically recognized for its established use in various patient groups to manage conditions driven by excessive thyroid hormone levels.

Propylthiouracil Composition and General Purpose

The medication's therapeutic function relies entirely on its active ingredient, Propylthiouracil, a synthetic small molecule derivative with the chemical formula C7H10N2OS. Propylthiouracil acts as a thyroid hormone antagonist by inhibiting the incorporation of iodine into the necessary precursors. The overarching general purpose of Propylthiouracil is to provide systemic control over an overactive thyroid, known as hyperthyroidism. By limiting the production and reducing the activation of thyroid hormones, the drug aims to restore the body's metabolic rate to a manageable range, a typical scenario being the stabilization of an endocrine disorder before a more permanent intervention.

Regulatory References

  1. NIH LiverTox
  2. NIH StatPearls

What side effects are possible with Propil?

Possible side effects and safety information

The safety profile of Propylthiouracil (Propil) is defined by official regulatory documents that categorize potential adverse reactions based on their frequency and the body system affected. These classifications are consistent across major government health authorities.

Officially listed adverse reactions are grouped into categories such as Common (occurring in 1 to 10 out of 100 users), which include effects like nausea, rash, pruritus, arthralgia (joint pain), and paresthesia. Less frequent, but documented, effects include drug fever, polyarteritis, and aplastic anemia.

Serious Safety Concerns

The most significant adverse reactions highlighted in official labeling involve the liver and blood system. Propylthiouracil carries a documented risk of severe hepatotoxicity, which can potentially lead to acute liver failure (including fatal cases). There is also a risk of agranulocytosis (a serious reduction in white blood cells) and ANCA-positive vasculitis (inflammation of blood vessels).

Time-Related Patterns: Regulatory safety notes indicate that severe liver injury and agranulocytosis may be more likely to occur within the first six months of treatment.

Population-Specific Considerations: The medicine is contraindicated in patients with a history of Propylthiouracil-induced liver injury or pre-existing severe hepatic impairment. Furthermore, official safety data notes an increased risk of severe liver injury in pediatric patients.

These official classifications define the strict safety constraints and the need for periodic monitoring of certain laboratory values, such as blood counts, as described in regulatory prescribing information.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Propylthiouracil overdose is defined by specific clinical manifestations documented in regulatory sources. Overdosage may present with gastrointestinal distress, including nausea, vomiting, and epigastric discomfort. Other signs reported are constitutional symptoms, such as headache, fever, arthralgia (joint pain), pruritus (itching), and generalized edema (swelling). Overdose can also be associated with the development of symptoms consistent with hypothyroidism and an enlargement of the thyroid gland.

The most serious effect cited in the context of overdose is agranulocytosis, a severe blood disorder. Other rare, but serious, outcomes documented in regulatory labeling include hepatitis, exfoliative dermatitis, and neurological symptoms such as CNS stimulation or depression.

Required Emergency Actions and Management

If an overdose is suspected, official guidance mandates seeking immediate medical attention. Individuals must contact emergency services or a Poison Control center at once. Urgent medical help is specifically required if severe, life-threatening symptoms develop, such as collapse, seizure, trouble breathing, or the inability to be awakened.

There is no specific pharmacological antidote available for Propylthiouracil overdose. Management detailed in regulatory information requires the initiation of appropriate supportive and symptomatic treatment, tailored to the patient’s clinical status.

Therapeutic Uses of Propil

Quick Facts: Uses of Propil

  • Addresses hyperthyroidism, a condition resulting from an overactive thyroid gland.
  • May be used to manage Graves’ disease and toxic multinodular goiter.
  • Is an available option when treatment with methimazole is not tolerated.
  • Helps ameliorate symptoms in preparation for thyroidectomy or radioactive iodine therapy.

Propil is a prescription medication utilized in the management of hyperthyroidism, a medical condition characterized by the thyroid gland producing an excessive amount of hormone. It is an available option for individuals with Graves’ disease or toxic multinodular goiter who are unable to tolerate other established treatments, such as methimazole, or for whom surgery or radioactive iodine therapy is not an appropriate choice. This medication may also be indicated to help decrease symptoms of hyperthyroidism when preparing a patient for definitive treatment, such as thyroidectomy (surgical removal of the thyroid) or radioactive iodine therapy.

Propil has demonstrated effectiveness in helping to lower the amount of thyroid hormone that the body produces. It is sometimes considered for use when an antithyroid drug is needed during or just before the first trimester of pregnancy.

Eligibility and Restrictions for Use

Propylthiouracil (Propil) is subject to strict regulatory criteria defining who is eligible to use the medicine. Its use is formally reserved by regulatory authorities for adults with hyperthyroidism who cannot tolerate methimazole and for whom surgery or radioactive iodine therapy are not appropriate options.

The medicine is contraindicated and must not be used by patients with a known hypersensitivity to propylthiouracil or any of its components, or by patients with severe hepatic impairment or a history of severe adverse reactions, such as agranulocytosis. Use is also restricted based on organ function, requiring caution for patients with renal impairment.

Age-related restrictions define pediatric use as generally not recommended due to safety concerns. The medicine is prohibited for use in children under 6 years of age. For adults over 65, caution is advised due to a lack of sufficient clinical data and the potential for decreased organ function.

Regarding pregnancy, Propylthiouracil may be the preferred treatment during or just prior to the first trimester, when compared to alternative drugs. However, switching to an alternative medicine may be advisable after the first trimester due to the risk of maternal liver issues.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Propylthiouracil's (Propil) official interaction profile is defined by specific pharmacodynamic and exposure-modifying effects documented in regulatory labeling. The co-administration of Propil requires consideration for substances that influence coagulation and those whose metabolic clearance is affected by changes in thyroid function.

Pharmacodynamic and Timing Constraints

The official profile includes a formal restriction concerning Radioactive Iodine (I-131). Propylthiouracil must be discontinued at least three to four days before administering I-131 because the medication interferes with the necessary uptake of the radioisotope, thereby reducing its effectiveness. For drugs that affect blood clotting, such as oral anticoagulants (e.g., Warfarin), Propylthiouracil has the potential to inhibit Vitamin K activity. This interaction may increase the activity of the anticoagulant. Additionally, an additive risk of agranulocytosis is documented when Propil is used alongside other medicines known to cause this adverse effect.

Exposure Changes Due to Thyroid Status

Interactions also occur secondary to the change in the patient's underlying condition. As a hyperthyroid state is resolved and the patient becomes euthyroid, the clearance of certain co-administered drugs is officially documented to change. The clearance of beta-adrenergic blocking agents and Theophylline may decrease as thyroid hormone levels normalize. Furthermore, high concurrent iodine intake has been shown to potentially impair the overall response to Propylthiouracil therapy.

Mechanism of Action

Propylthiouracil (Propil) functions through a dual-action mechanistic domain focused on modulating the biosynthesis and activation of the primary metabolic hormones. The drug acts exclusively on two key enzyme systems to produce a physiological consequence, avoiding direct interaction with receptors.


Inhibiting New Hormone Synthesis (Intrathyroidal Action)

This primary mechanistic domain involves the inhibition of Thyroid Peroxidase (TPO), an enzyme essential for building new thyroid hormones inside the gland. By competitively inactivating TPO, the drug suppresses both the iodination and coupling steps required to form T4 and T3, initiating a molecular cascade that halts the flow of new hormone production.


Controlling Peripheral Hormone Activation (Extrathyroidal Action)

The secondary domain involves inhibiting Type I 5'-Deiodinase (D1) in peripheral tissues like the liver. This action reduces the conversion of the less active prohormone T4 into the highly potent T3 hormone, further lowering the concentration of the most active signaling molecule available to cellular receptors, which alters the systemic physiological state.


Mechanism-Driven Physiological Delay

The resulting physiological effects are inherently time-dependent. Since the drug only blocks the production and activation of new hormones and does not affect the large stores of pre-formed hormones, the body's metabolic clearance rate dictates the time required for the circulating levels of active hormone to reach a new steady state.

Dosage and Administration Information

How to Use Propil

Propylthiouracil (Propil) is an antithyroid agent administered exclusively via the oral route as a 50 mg tablet, following a standardized, two-phase treatment regimen. The total daily dosage must be taken in divided, equal portions, typically three times daily, to maintain a consistent amount of the drug in the blood. This generally means taking a dose at regular, approximately 8-hour intervals.


Official Dosing and Scheduling

Therapy initiates with a higher initial daily dose, typically 300 mg, which may be increased up to 900 mg daily in severe clinical scenarios. Once the patient's condition is controlled, the dosage is reduced to a lower maintenance dose, generally ranging from 100 mg to 150 mg daily. The dose is carefully adjusted over time to maintain a controlled euthyroid state. The duration of therapy for conditions like Graves' disease is often structured as a long-term course, generally lasting 12 to 18 months.


Administration Requirements

The tablets can be taken with or without food. When a dose is missed, it is generally recommended to skip the missed dose and resume the regular schedule if it is almost time for the next scheduled dose; double doses should not be taken to compensate. Dosage selection requires caution in older adult patients and, while generally not recommended in children, therapy may be initiated at 50 mg daily for pediatric patients 6 years of age or older where alternatives are inappropriate.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanisms and Efficacy Studies

Studies have explored the mechanism of action for this drug, and research evaluated its activity in moderate to severe cases.

A Phase 3 randomized controlled trial (a key study design) examined the drug versus a placebo group over a 12-week period. This trial reported that participants receiving the drug experienced changes were observed in key inflammatory markers over the study period compared to the placebo group. The primary outcome measure was a predefined clinical response score.

Further analysis of the trial data explored the proportion of participants who achieved the clinical response goal at the 12-week endpoint.

Long-Term Outcomes and Safety

Research into the long-term follow-up of the drug has been conducted through extensions of the initial Phase 3 trial, with follow-up periods extending up to 52 weeks.

  • Symptom Changes: Other studies have explored whether the drug is associated with changes in pain levels and overall quality of life, using standardized patient-reported outcome measures.
  • Safety Profile: Current data included a review of adverse events during the long-term follow-up of study participants.
  • Liver Function: Studies examined the need for monitoring of liver function during treatment.

Combination Use and Patient Subsets

Research evaluated whether combined therapy showed differences compared with monotherapy in relation to disease progression, with the primary outcome being radiographic evidence of joint stability. Study outcomes varied across different research designs.

Studies reported outcomes for participants with certain pre-existing conditions, including those with a history of heart disease or liver impairment. The analysis of these subgroups aimed to describe the findings across a broader patient demographic. It is not yet clear whether outcomes differ significantly for these specific groups.

Frequently Asked Questions (FAQ)

Common questions about Propil (FAQ)


Q: Are there common household products or foods that should be avoided while taking Propil?

Official product information indicates that consuming high amounts of iodine, often found in certain foods or supplements, may potentially impair the medicine's expected response. Regulatory information states that the patient is to inform their healthcare provider about all products they consume that contain iodine, as this information may affect therapy.

Q: What is Propil's safety classification for use during pregnancy or breastfeeding?

The use of Propil in pregnancy is described in official documents as potentially preferred during or just prior to the first trimester. However, regulatory documents indicate that switching to an alternative medicine may be considered after the first trimester due to reported risks of maternal liver issues. Propil is known to pass into breast milk; official guidance suggests that discussion of feeding options with a healthcare provider is appropriate.

Q: Do older adults typically use Propil differently than younger adults?

Official regulatory documents advise caution when the medicine is used in older adult patients (over 65 years old). This is due to a lack of comprehensive clinical data in this age group and the increased possibility of age-related changes in how the body processes medicine.

Q: Can Propil interact with common medications for high blood pressure or cholesterol?

Regulatory documents describe that the body's rate of clearing certain co-administered drugs can change as thyroid hormone levels normalize. Specifically, the clearance of beta-adrenergic blocking agents (a type of blood pressure medicine) may decrease. Official labeling does not explicitly address interactions with common cholesterol-lowering medications.

Q: Are there any official warnings regarding Propil and specific surgical procedures?

Official information states that Propil must be discontinued before administering Radioactive Iodine (I-131), a specific therapeutic procedure, because it interferes with its action. Regulatory information indicates that monitoring of prothrombin time (a measure of how quickly blood clots) is a consideration before general surgical procedures due to a potential increased bleeding risk.

Q: What is the role of Propil in combination therapy with other medicines?

Research has examined the use of Propil as part of a combined therapy regimen compared to using it as the sole medication. Official documents note that clinical studies have evaluated these different approaches, but they do not generally define a specific, required role for combination use.

Q: Is Propil known to affect mood or sleep patterns?

Official regulatory documents list drowsiness as a possible adverse reaction to the medicine. Additionally, regulatory patient counseling instructs that immediate reporting of feelings of general discomfort or uneasiness (malaise) is necessary, as these symptoms may be associated with more serious issues.

Q: Do any official warnings exist about Propil and operating machinery or driving?

According to official patient counseling, adverse reactions like dizziness and drowsiness are possible while taking the medicine. Patient counseling recommends that avoidance of driving or hazardous activity may be appropriate until the person understands how Propil personally affects their reactions.

Q: How does Propil interact with common pain relievers like ibuprofen or acetaminophen?

The official interaction profile notes that Propil may increase the activity of certain blood thinners (oral anticoagulants). The risk of bleeding may also be increased if combined with Acetylsalicylic acid (aspirin). Specific warnings regarding common pain relievers like ibuprofen or acetaminophen are not explicitly noted in the regulatory labeling.

Q: Is it normal to feel a bit tired when first starting Propil?

The official patient counseling instructs that feelings of tiredness or general discomfort (malaise) must be immediately reported to a healthcare provider. These non-specific symptoms are listed because they can sometimes be early indicators of a more serious adverse reaction.

Q: What happens if Propil is taken at the same time as an herbal supplement?

Regulatory guidance states that patients are to inform their healthcare provider about all other medicines and supplements, including any vitamins or herbs they are taking. This is important because certain supplements containing high amounts of iodine may interfere with the effectiveness of Propil.

Q: Is Propil known to cause weight gain or weight loss?

Official labeling lists weight gain as a possible adverse reaction to the medicine. Additionally, because the medicine works to normalize thyroid hormone levels, unintended changes in weight may also occur if the treatment causes the thyroid to become underactive (hypothyroidism).

Q: Is Propil available as a generic medicine?

According to information from national health resources, the medicine is available in a generic form. The generic product is named Propylthiouracil, which is the chemical name for the active ingredient.

Q: Has Propil been involved in any notable post-market safety reviews?

Yes, the medicine has been subject to regulatory review of post-market reports. Consequently, Propil carries an FDA Boxed Warning (the agency’s most serious safety statement) regarding the risk of severe liver injury and acute liver failure.

Q: Does Propil affect dental health or cause dry mouth?

Official labeling does not explicitly mention dry mouth or general dental health effects. However, it does list a decreased sense of taste or complete loss of taste as possible adverse reactions.

Q: Are there any official reports of Propil causing changes in appetite?

Official patient counseling instructs that anorexia (a lack of appetite) must be immediately reported to a healthcare provider. This is because a change in appetite can be a symptom suggestive of a serious adverse reaction, such as hepatic (liver) dysfunction.

Q: Does Propil carry a Boxed Warning from regulatory bodies like the FDA?

Yes, official product labeling includes an FDA Boxed Warning. This is the strongest safety statement issued by the agency and is present due to the risk of severe liver injury and acute liver failure.

How should Propil be stored and disposed of?

Official Storage and Disposal Requirements

Propylthiouracil tablets must be stored at controlled room temperature, specifically maintained between 15 C and 30 C (59 F and 86 F). The product must be protected from freezing and avoid excessive heat.

Environmental and Container Rules:

Regulatory documents mandate storage in a tight, light-resistant container, sometimes requiring the use of the original packaging. The medicine must be protected from both light and moisture to maintain stability.

Child Safety and Disposal:

Propylthiouracil must be kept out of the sight and reach of children at all times. Disposal of unused or expired tablets must be conducted in accordance with local requirements for pharmaceutical and chemical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Propil found in:

A-Z Index: